<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2144">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05133245</url>
  </required_header>
  <id_info>
    <org_study_id>211300</org_study_id>
    <nct_id>NCT05133245</nct_id>
  </id_info>
  <brief_title>PHACE - Prospective Genetic Investigation</brief_title>
  <acronym>PHACE</acronym>
  <official_title>PHACE - Prospective Genetic Investigation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigation for potential PHACE syndrome gene.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with PHACE syndrome diagnosis will undergo a brief physical examination with&#xD;
      possible external photographs. Cheek swabs will be sent for genetic analysis. Subjects will&#xD;
      be notified of the results.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">November 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Potential PHACE Gene Identification</measure>
    <time_frame>3 years</time_frame>
    <description>Evaluation for potential PHACE gene</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>PHACE Syndrome</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diagnostic study only</intervention_name>
    <description>Diagnostic study only</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Cheek swabs&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All age groups, genders, and ethnicities who qualify with the PHACE syndrome diagnosis and&#xD;
        consent to undergo an examination and genetic testing.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PHACE syndrome diagnosis&#xD;
&#xD;
          -  Must be willing to have an eye examination&#xD;
&#xD;
          -  Must be willing to undergo genetic testing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No PHACE syndrome diagnosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Joos, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt Eye Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt Eye Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 1, 2021</study_first_submitted>
  <study_first_submitted_qc>November 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Karen Joos</investigator_full_name>
    <investigator_title>Primary Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

